>
Neurobiological Technologies Inc logo

NTII - Neurobiological Technologies Inc Share Price

$0 0.0  0.0%

Last Trade - 22/09/21

Sector
Healthcare
Size
Micro Cap
Market Cap £3.95k
Enterprise Value £-2.37m
Revenue £18.5m
Position in Universe th / 7245
Bullish
Bearish
Unlock NTII Revenue
Momentum
Relative Strength (%)
1m +37.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2004 2005 2006 2007 2008 2009 2010E 2011E CAGR / Avg
2.79 3.10 12.3 17.7 14.8 26.4 +56.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 17 December 2009,Neurobiological Technologies, Inc. revenues decreased 15%to $6M. Net income totaled $4.9M vs. loss of $10.6M.Revenues reflect Technology sale and collaboration servicdecrease of 100% to $7K. Net Income reflects Research anddevelopment decrease from $15.8M (expense) to $0K, Noncashgain (loss) on change in fair va increase from $37K to$295K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NTII Revenue Unlock NTII Revenue

Net Income

NTII Net Income Unlock NTII Revenue

Normalised EPS

NTII Normalised EPS Unlock NTII Revenue

PE Ratio Range

NTII PE Ratio Range Unlock NTII Revenue

Dividend Yield Range

NTII Dividend Yield Range Unlock NTII Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NTII EPS Forecasts Unlock NTII Revenue
Profile Summary

Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.

Directors
Last Annual June 30th, 2009
Last Interim December 17th, 2009
Incorporated January 25, 1994
Public Since February 16, 1994
No. of Shareholders: 200
No. of Employees: 4
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 27,019,805
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
NTII Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NTII
Upcoming Events for NTII
Frequently Asked Questions for Neurobiological Technologies Inc
What is the Neurobiological Technologies Inc share price?

As of 22/09/21, shares in Neurobiological Technologies Inc are trading at $0, giving the company a market capitalisation of £3.95k. This share price information is delayed by 15 minutes.

How has the Neurobiological Technologies Inc share price performed this year?

Shares in Neurobiological Technologies Inc are currently trading at $0 and the price has moved by -95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neurobiological Technologies Inc price has moved by -95.97% over the past year.

What are the analyst and broker recommendations for Neurobiological Technologies Inc?

Of the analysts with advisory recommendations for Neurobiological Technologies Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Neurobiological Technologies Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Neurobiological Technologies Inc next release its financial results?

Neurobiological Technologies Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2010-12-17
What is the Neurobiological Technologies Inc dividend yield?

Neurobiological Technologies Inc does not currently pay a dividend.

Does Neurobiological Technologies Inc pay a dividend?

Neurobiological Technologies Inc does not currently pay a dividend.

When does Neurobiological Technologies Inc next pay dividends?

Neurobiological Technologies Inc does not currently pay a dividend.

How do I buy Neurobiological Technologies Inc shares?

To buy shares in Neurobiological Technologies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neurobiological Technologies Inc?

Shares in Neurobiological Technologies Inc are currently trading at $0, giving the company a market capitalisation of £3.95k.

Where are Neurobiological Technologies Inc shares listed? Where are Neurobiological Technologies Inc shares listed?

Here are the trading details for Neurobiological Technologies Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: NTII
What kind of share is Neurobiological Technologies Inc?

We were not able to load our ranking data for Neurobiological Technologies Inc

Is there a Neurobiological Technologies Inc share price forecast 2021?

We were not able to load any forecast data for Neurobiological Technologies Inc.

How can I tell whether the Neurobiological Technologies Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurobiological Technologies Inc. Over the past six months, the relative strength of its shares against the market has been -98.21%. At the current price of $0, shares in Neurobiological Technologies Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neurobiological Technologies Inc PE Ratio?

We were not able to find PE ratio data for Neurobiological Technologies Inc.

Who are the key directors of Neurobiological Technologies Inc?

Neurobiological Technologies Inc's management team is headed by:

John Stuppin - DRC
William Fletcher - DRC
Matthew Loar - CEO
Who are the major shareholders of Neurobiological Technologies Inc?

Here are the top five shareholders of Neurobiological Technologies Inc based on the size of their shareholding:

Ancora Advisors, L.L.C. Investment Advisor/Hedge Fund
Percentage owned: 9.42% (2.54m shares)
Similar to NTII
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.